onconephrology

Can Checkpoint Inhibitors Pave the Way for A Generation of Targeted Therapies for Autoimmune Diseases?

October 15, 2019 // 3 Comments

When I was a medical resident, a novel developmental therapy for the treatment of certain cancers was to medically shut off the blood supply and cause ischemia to the mass. Avastin (bevacizumab), or anti-VEGF (vascular endothelial growth factor) [read more...]

Light Chain Proximal Tubulopathy – The Tip of the Iceberg?

November 8, 2016 // 1 Comment

In recent years, there has been increased recognition of the spectrum of kidney diseases associated with paraproteinemias. The fact that the pathogenetically related categories of “monoclonal immunoglobulin deposition disease” and “light chain [read more...]

Hemaphagocytic Syndrome and the Kidney: Is There a Connection?

May 31, 2016 // 0 Comments

Hemophagocytic syndrome (HPS), also known as hemophagocytic lymphohistiocytosis (HLH), is one of those rare diseases that one sees at the bottom of differential diagnoses in textbooks or UpToDate. Indeed, it does remind one of the adage “the [read more...]

#SCM16: Eculizumab for Chemo-Induced aHUS

April 30, 2016 // 0 Comments

Dr. Sylvester Ogbata (SO), from the University of Tennessee Health Science Center in Memphis, Tennessee, discusses his abstract for the National Kidney Foundation’s 2016 Spring Clinical Meetings (SCM16), Gemcitabine Induced Atypical Hemolytic [read more...]

Renal Amyloidosis – What We Need to Consider, Practical Tips

January 21, 2016 // 2 Comments

The AJKD Atlas of Renal Pathology II has recently provided a succinct summary of the diagnosis of AL (light chain) amyloidosis, the most common type of renal amyloidosis, and compared it with hereditary and other non-AL amyloidosis. Related [read more...]

Test Your Knowledge: Onco-Nephrology

August 10, 2015 // 0 Comments

The overlap of hematology, oncology, and nephrology has led to the creation of a field called Onconephrology. Cancer survivors are living longer and developing chronic kidney disease. Novel chemotherapy agents are nephrotoxic. The field of [read more...]

Thrombotic Microangiopathy in Cancer Patients

July 6, 2015 // 2 Comments

Thrombotic microangiopathy (TMA) describes a set of disorders that are characterized by microvascular thrombosis, microangiopathic hemolytic anemia, thrombocytopenia, and organ damage, most often to the kidney. Though TMA was classically divided [read more...]

Glomerular Diseases and Complement Activation

July 2, 2015 // 0 Comments

A recent Core Curriculum by Noris and Remuzzi is on the timely topic of activation of the complement system in glomerular disease. This focuses on our evolving understanding of atypical hemolytic uremic syndrome (aHUS), membranoproliferative [read more...]

Cancer Incidence Among US Medicare Hemodialysis Patients

May 21, 2015 // 0 Comments

In their recent study “Cancer Incidence Among US Medicare ESRD Patients Receiving Hemodialysis, 1996-2009” published in the May issue of AJKD, Butler et al provide the largest and most recent estimate of the incidence of different [read more...]

Test Your Knowledge: Polyomavirus-Associated Nephropathy

May 14, 2015 // 0 Comments

Polyomavirus-associated nephropathy (PVAN) is common in kidney transplant patients, but infrequent following hematopoietic stem cell transplantation (HSCT). Aside from reduction of immunosuppression, few therapeutic options exist for treatment of [read more...]

AJKD Blog

Official Blog of the American Journal of Kidney Diseases